Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2010

01.01.2010 | Bone and Soft Tissue Sarcomas

Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers

verfasst von: Silvia Stacchiotti, MD, Paolo Giovanni Casali, MD, Salvatore Lo Vullo, BSc, Luigi Mariani, MD, Elena Palassini, MD, Mario Mercuri, MD, Marco Alberghini, MD, Silvana Pilotti, MD, Licciana Zanella, MD, Alessandro Gronchi, MD, Piero Picci, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Chordoma is a rare tumor, and its natural history is still not well known.

Materials and Methods

All patients affected by localized chordoma surgically treated at Istituto Ortopedico Rizzoli, Bologna, and Istituto Nazionale Tumori, Milan, Italy, between 1980 and 2008 were reviewed. Local recurrence, distant metastasis, and overall survival (OS) were analyzed both from time of diagnosis and from time of local recurrence/distant metastasis. A multivariable analysis to identify independent prognostic factors was carried out.

Results

A total of 138 consecutive patients were identified (sacrum 78%, lumbar spine 15%, cervical-dorsal spine 7%). Of these, 130 underwent surgical resection. Median follow-up was 142 months. The 5- and 10-year OS, local relapse-free survival (LRFS), and distant relapse-free survival (DRFS) were, respectively, 78% and 54%, 52% and 33%, and 86% and 72%. Size was an independent prognostic factor for OS (P value < .001), LRFS (P value: .038), and DRFS (P value: .004), while surgical margins independently predicted LRFS (P value: .003) with a trend for OS. The 5- and 10-year OS, LRFS, and DRFS after the first local relapse were 50% and 26%, 47% and 31%, and 64% and 61%. The size of the recurrence and quality of surgical margins did not influence postrelapse OS. The 5-year OS after the second local relapse was 19%. 22% of patients developed distant metastases with a 5-year post-metastases OS of 33%.

Conclusions

Tumor size and surgical margins affected outcome only on initial presentation. However, wide surgery was feasible in a minority of cases. Most patients died of local–regional disease even when metastases occurred. Indeed, long-term prognosis was such that disease-free survival at 10 years was only 26%.
Literatur
1.
Zurück zum Zitat Newton H. Chordoma. In: Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, et al., editors. Textbooks of uncommon cancer. 3rd ed. Chichester: John Wiley & Sons Ltd; 2006. p. 614–25. Newton H. Chordoma. In: Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, et al., editors. Textbooks of uncommon cancer. 3rd ed. Chichester: John Wiley & Sons Ltd; 2006. p. 614–25.
2.
Zurück zum Zitat Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdraw K, Pizzolitto S, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:573–80. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdraw K, Pizzolitto S, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:573–80.
3.
Zurück zum Zitat Mirra JM, Della Rocca C, Nelson SD, Mertens F. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. p. 316–7. Mirra JM, Della Rocca C, Nelson SD, Mertens F. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. p. 316–7.
4.
Zurück zum Zitat Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 200;209:157–65. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 200;209:157–65.
5.
Zurück zum Zitat Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 2006;12:6920–8.CrossRefPubMed Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 2006;12:6920–8.CrossRefPubMed
6.
Zurück zum Zitat Tamayama C, Maruyama K. Expression of EGF receptor and c-neu oncogene product in chordomas. Gan No Rinsho. 1990;36:773–6.PubMed Tamayama C, Maruyama K. Expression of EGF receptor and c-neu oncogene product in chordomas. Gan No Rinsho. 1990;36:773–6.PubMed
7.
Zurück zum Zitat Tamborini E, Virdis E, Orsenigo M, et al. Analysis of receptor tyrosine kinases (RTK) and downstream pathways in chordomas. Submitted to Neuroncology. Tamborini E, Virdis E, Orsenigo M, et al. Analysis of receptor tyrosine kinases (RTK) and downstream pathways in chordomas. Submitted to Neuroncology.
8.
Zurück zum Zitat Higinbotham NL, Philips RF, Farr HW, Hustu HO. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer. 1967;20:1841–50.CrossRefPubMed Higinbotham NL, Philips RF, Farr HW, Hustu HO. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer. 1967;20:1841–50.CrossRefPubMed
9.
Zurück zum Zitat Chambers PW, Schwinn CP. Chordoma. A clinico-pathologic study of metastasis. Am J Clin Path. 1979;72:765–76.PubMed Chambers PW, Schwinn CP. Chordoma. A clinico-pathologic study of metastasis. Am J Clin Path. 1979;72:765–76.PubMed
10.
Zurück zum Zitat Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003;10:291–6.CrossRefPubMed Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003;10:291–6.CrossRefPubMed
11.
Zurück zum Zitat Bjornsson J, Wold LE, Ebersold MJ, Laws ER. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993;71:735–40.CrossRefPubMed Bjornsson J, Wold LE, Ebersold MJ, Laws ER. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993;71:735–40.CrossRefPubMed
12.
Zurück zum Zitat Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122–34.CrossRefPubMed Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122–34.CrossRefPubMed
13.
Zurück zum Zitat McPherson CM, Suki D, McCutcheon I.E, Gokaslan ZL, Rhines LD, Medel E. Metastatic disease from spinal chordoma: a 10-year experience. J Neurosurg Spine. 2006;5:277–80.CrossRefPubMed McPherson CM, Suki D, McCutcheon I.E, Gokaslan ZL, Rhines LD, Medel E. Metastatic disease from spinal chordoma: a 10-year experience. J Neurosurg Spine. 2006;5:277–80.CrossRefPubMed
14.
Zurück zum Zitat York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74–9.CrossRefPubMed York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74–9.CrossRefPubMed
15.
Zurück zum Zitat Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery. 2006;59:230–7.CrossRefPubMed Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery. 2006;59:230–7.CrossRefPubMed
16.
Zurück zum Zitat Boriani S, Bandiera S, Biagini R, Bacchini P, Boriani L, Cappuccio M, et al. Chordoma of the mobile spine: fifty years of experience. Spine. 2006;31:493–503.CrossRefPubMed Boriani S, Bandiera S, Biagini R, Bacchini P, Boriani L, Cappuccio M, et al. Chordoma of the mobile spine: fifty years of experience. Spine. 2006;31:493–503.CrossRefPubMed
17.
Zurück zum Zitat Samii A, Gerganov VM, Herold C, Hayashi N, Naka T, Mirzayan MJ, et al. Chordomas of the skull base: surgical management and outcome. J Neurosurg. 2007;107:319–24.CrossRefPubMed Samii A, Gerganov VM, Herold C, Hayashi N, Naka T, Mirzayan MJ, et al. Chordomas of the skull base: surgical management and outcome. J Neurosurg. 2007;107:319–24.CrossRefPubMed
18.
Zurück zum Zitat Vergara G, Belinchón B, Valcárcel F, Veiras M, Zapata I, de la Torre A. Metastatic disease from chordoma. Clin Transl Oncol. 2008;10:517–21.CrossRefPubMed Vergara G, Belinchón B, Valcárcel F, Veiras M, Zapata I, de la Torre A. Metastatic disease from chordoma. Clin Transl Oncol. 2008;10:517–21.CrossRefPubMed
19.
Zurück zum Zitat Pearlman A, Friedman M. Radical radiation therapy of chordoma. Am J Roentgenol Radium Ther Nucl Med. 1970;108:332–41.PubMed Pearlman A, Friedman M. Radical radiation therapy of chordoma. Am J Roentgenol Radium Ther Nucl Med. 1970;108:332–41.PubMed
20.
Zurück zum Zitat Rich TA, Schiller A, Suit HD, Mankin HJ. Clinical and pathologic review of 48 cases of chordoma. Cancer. 1985;56:182–7.CrossRefPubMed Rich TA, Schiller A, Suit HD, Mankin HJ. Clinical and pathologic review of 48 cases of chordoma. Cancer. 1985;56:182–7.CrossRefPubMed
21.
Zurück zum Zitat Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:633–42.PubMed Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:633–42.PubMed
22.
Zurück zum Zitat Catton C, O’Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, et al. Chordoma: Long-term follow-up after radical photon irradiation. Radiother Oncol. 1996;41:67–72.PubMed Catton C, O’Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, et al. Chordoma: Long-term follow-up after radical photon irradiation. Radiother Oncol. 1996;41:67–72.PubMed
23.
Zurück zum Zitat DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009;74:732–9.PubMed DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009;74:732–9.PubMed
24.
Zurück zum Zitat Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 2009 [Epub ahead of print]. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 2009 [Epub ahead of print].
25.
Zurück zum Zitat Crockard HA, Steel T, Plowman N, Singh A, Crossman J, Revesz T, et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg. 2001;95:175–83.CrossRefPubMed Crockard HA, Steel T, Plowman N, Singh A, Crossman J, Revesz T, et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg. 2001;95:175–83.CrossRefPubMed
26.
Zurück zum Zitat Foweraker KL, Burton KE, Maynard SE, Jena R, Jefferies SJ, Laing RJ, et al. High-dose radiotherapy in the management of chordoma and chondrosarcoma of the skull base and cervical spine: Part 1—Clinical outcomes. Clin Oncol (R Coll Radiol). 2007;19:509–16. Foweraker KL, Burton KE, Maynard SE, Jena R, Jefferies SJ, Laing RJ, et al. High-dose radiotherapy in the management of chordoma and chondrosarcoma of the skull base and cervical spine: Part 1—Clinical outcomes. Clin Oncol (R Coll Radiol). 2007;19:509–16.
27.
Zurück zum Zitat Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999;91:432–9.CrossRefPubMed Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999;91:432–9.CrossRefPubMed
28.
Zurück zum Zitat Noel G, Habrand JL, Mammar H, Pontvert D, Haie-Méder C, Hasboun D, et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: The Centre de Protontherapie D’Orsay experience. Int J Radiat Oncol Biol Phys. 2001;51:392–8.PubMed Noel G, Habrand JL, Mammar H, Pontvert D, Haie-Méder C, Hasboun D, et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: The Centre de Protontherapie D’Orsay experience. Int J Radiat Oncol Biol Phys. 2001;51:392–8.PubMed
29.
Zurück zum Zitat Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086–97.CrossRefPubMed Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086–97.CrossRefPubMed
30.
Zurück zum Zitat Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie. 2006;29:572–4.CrossRefPubMed Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie. 2006;29:572–4.CrossRefPubMed
31.
Zurück zum Zitat Lindén O, Stenberg L, Kjellén E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol. 2009;48:158–9.CrossRefPubMed Lindén O, Stenberg L, Kjellén E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol. 2009;48:158–9.CrossRefPubMed
32.
Zurück zum Zitat Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed
33.
Zurück zum Zitat Kasimis BS, Chang V, Gounder S, Hoover D, Finch-Cruz C, Cogswell J, et al. Correlation between prostate cancer immunohistochemical stains (IHC) and survival in stage D2 patients. 2008 ASCO annual meeting proceedings. J Clin Oncol. 2008;26:abstract 16093. Kasimis BS, Chang V, Gounder S, Hoover D, Finch-Cruz C, Cogswell J, et al. Correlation between prostate cancer immunohistochemical stains (IHC) and survival in stage D2 patients. 2008 ASCO annual meeting proceedings. J Clin Oncol. 2008;26:abstract 16093.
34.
Zurück zum Zitat Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, et al. Prediction of survival by immunohistochemical stains in stage D2 prostate cancer patients: The importance of pTEN overexpression. 2009 ASCO annual meeting proceedings. J Clin Oncol. 2009:abstract 16019. Kasimis B, Chang V, Gounder S, Gonzalez M, Finch-Cruz C, Blumenfrucht M, et al. Prediction of survival by immunohistochemical stains in stage D2 prostate cancer patients: The importance of pTEN overexpression. 2009 ASCO annual meeting proceedings. J Clin Oncol. 2009:abstract 16019.
35.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.CrossRef
36.
Zurück zum Zitat Marubini E, Valsecchi MG. Analysing survival data for clinical trials and observational studies. Chichester: John Wiley and Sons, 1995. Marubini E, Valsecchi MG. Analysing survival data for clinical trials and observational studies. Chichester: John Wiley and Sons, 1995.
37.
Zurück zum Zitat Colli B, Al-Mefty O. Chordomas of the craniocervical junction: follow-up review and prognostic factors. J Neurosurg. 2001;95:933–43.CrossRefPubMed Colli B, Al-Mefty O. Chordomas of the craniocervical junction: follow-up review and prognostic factors. J Neurosurg. 2001;95:933–43.CrossRefPubMed
38.
Zurück zum Zitat Wagner TD, Kobayashi W, Dean S, Goldberg SI, Kirsch DG, Suit HD, et al. Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. Int J Radiat Oncol Biol Phys. 2009;73:259–66.PubMed Wagner TD, Kobayashi W, Dean S, Goldberg SI, Kirsch DG, Suit HD, et al. Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. Int J Radiat Oncol Biol Phys. 2009;73:259–66.PubMed
39.
Zurück zum Zitat Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597–604.CrossRefPubMed Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597–604.CrossRefPubMed
40.
Zurück zum Zitat Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME. Chemotherapeutic treatment of malignant chordomas in children. J Pediatr Hematol Oncol. 1996;18:237–40.CrossRefPubMed Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME. Chemotherapeutic treatment of malignant chordomas in children. J Pediatr Hematol Oncol. 1996;18:237–40.CrossRefPubMed
41.
Zurück zum Zitat Razis DV, Tsatsaronis A, Kyriazides I, Triantafyllou D. Chordoma of the cervical spine treated with vincristine sulphate. J Med. 1974;5:274–7.PubMed Razis DV, Tsatsaronis A, Kyriazides I, Triantafyllou D. Chordoma of the cervical spine treated with vincristine sulphate. J Med. 1974;5:274–7.PubMed
42.
Zurück zum Zitat McSweeney AJ, Sholl PR. Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordomas therapy. AMA Arch Surg. 1959;79:152–5.PubMed McSweeney AJ, Sholl PR. Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordomas therapy. AMA Arch Surg. 1959;79:152–5.PubMed
43.
Zurück zum Zitat Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995;9:765–85.PubMed Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995;9:765–85.PubMed
44.
Zurück zum Zitat Schonegger K, Gelpi E, Prayer D, Dieckmann K, Matula C, Hassler M, et al. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs. 2005;16:1139–43.CrossRefPubMed Schonegger K, Gelpi E, Prayer D, Dieckmann K, Matula C, Hassler M, et al. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs. 2005;16:1139–43.CrossRefPubMed
45.
Zurück zum Zitat Stacchiotti S, Ferrari S, Ferraresi V, Grignani G, Crippa F, Messina A, et al. Imatinib mesylate in advanced chordoma: a multicenter phase II study. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:abstract 10003. Stacchiotti S, Ferrari S, Ferraresi V, Grignani G, Crippa F, Messina A, et al. Imatinib mesylate in advanced chordoma: a multicenter phase II study. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:abstract 10003.
Metadaten
Titel
Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers
verfasst von
Silvia Stacchiotti, MD
Paolo Giovanni Casali, MD
Salvatore Lo Vullo, BSc
Luigi Mariani, MD
Elena Palassini, MD
Mario Mercuri, MD
Marco Alberghini, MD
Silvana Pilotti, MD
Licciana Zanella, MD
Alessandro Gronchi, MD
Piero Picci, MD
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0740-x

Weitere Artikel der Ausgabe 1/2010

Annals of Surgical Oncology 1/2010 Zur Ausgabe

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.